☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
galapagos
Galapagos Receives the US FDA’s IND Clearance of GLPG5101 to Treat R/R Non-Hodgkin lymphoma (NHL)
August 23, 2024
Galapagos Reports the First Patient Dosing of GLPG3667 in the P-II Study (GALARISSO) for the Treatment of Dermatomyositis
May 24, 2023
Galapagos Reports Initiation of P-III Trial (OLINGUITO) for Filgotinib to Treat Active Axial Spondyloarthritis
April 28, 2023
Galapagos Reports P-III Trial (DIVERSITY) Results of Filgotinib for the Treatment of Crohn’s Disease
February 9, 2023
Galapagos to Acquire CellPoint and AboundBio to Advance Cell Therapies for the Treatment of Advanced Cancer
June 22, 2022
Galapagos Reports Completion of Patient Enrollment in P-II MANGROVE Trial of GLPG2737 for the Treatment of Polycystic Kidney Disea...
November 24, 2021
Load more...
Back to Home
Modal title
×
Modal body text goes here.